Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.

Summary Of Consolidated Financial Statements For The First Nine Months Of Fiscal Year Ending December 31, 2024 [Japanese Gaap]

Summary Of Consolidated Financial Statements For The First Six Months Of Fiscal Year Ending December 31, 2024 [Japanese Gaap]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Symbio Pharmaceuticals (4582 JP)

Summary Of Consolidated Financial Statements For The First Nine Months Of Fiscal Year Ending December 31, 2024 [Japanese Gaap]

Summary Of Consolidated Financial Statements For The First Six Months Of Fiscal Year Ending December 31, 2024 [Japanese Gaap]

Revision To Earnings Forecast For Fy 2024

Summary Of Consolidated Financial Statements For The First Three Months Of Fiscal Year Ending December 31, 2024 [Japanese Gaap]

(Updated) Notice Of Recognition Of Impairment Loss, And Differences Between Consolidated Earnings Forecasts And Actual Results For Fy2023

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)